Tag: T-cell

Respiratory illnesses are on the rise in an increasingly polluted world. Particularly, viral respiratory infections tend to aggravate previously existing respiratory illnesses, or cause life-long negative after-effects in patients. In its extreme form, this could manifest as chronic obstructive pulmonary disease (COPD). Unfortunately, current treatments are primarily focused on alleviating the associated symptoms. To address

(HealthDay)—In a first, researchers have used genetically tweaked immune system cells to send a woman’s severe lupus into remission. The treatment—called CAR T-cell therapy—is already approved in the United States for fighting certain cases of blood cancer. It involves removing a patient’s own immune system T-cells, genetically altering them to target the cancer, then infusing

Chimeric antigen receptor T-cell therapy, or CAR T, was named the 2017 Advance of the Year by the American Society of Clinical Oncology. The FDA approved two CAR T products last year for treatment of adult large B-cell lymphoma based on the exceptional patient outcomes seen in clinical trials. Now, a follow-up study of one

(HealthDay)—The U.S. Food and Drug Administration on Friday expanded approval for the use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma (PTCL). The FDA stated in a press release that this approval is the first for treatment of newly diagnosed PTCL. Adcetris, a monoclonal

FT819, an off-the-shelf, T-cell receptor (TCR)-less CD19 CAR T-cell product that could potentially be made more accessible to cancer patients than conventional CAR T-cell therapies showed positive results in preclinical specificity, functionality, and efficacy studies, according to data presented at the AACR Annual Meeting 2018, April 14-18. “Chimeric antigen receptor (CAR) T-cell therapy has shown